Analytical Data
-
基因名
MET
- Application
-
别名
HGFR; RCCP2; Hepatocyte Growth Factor Receptor; Met Proto-Oncogene; Mesenchymal-Epithelial Transition Factor; HGF/SF receptor; Proto-oncogene c-Met; Scatter factor receptor; Tyrosine-protein kinase M
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P08581
-
表达区间
Val1092~Val1379
-
分子量
36kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The MET receptor tyrosine kinase, encoded by the MET gene, plays a crucial role in various cellular processes, including cell growth, motility, and survival. Its activation by hepatocyte growth factor (HGF) promotes several biological functions that are vital for normal development and tissue repair. However, aberrant MET signaling is implicated in various pathological conditions, particularly in cancer, where MET overexpression or mutations can lead to enhanced tumor progression, metastasis, and resistance to therapies. As a result, MET has emerged as a significant target for drug development in oncology. Research on MET recombinant proteins aims to better understand its structural and functional characteristics, allowing for the design of inhibitors that can effectively block its activity. Additionally, studying MET recombinant proteins can provide insights into the mechanisms of receptor activation and downstream signaling pathways, contributing to a more comprehensive understanding of the role of MET in both normal physiology and the pathogenesis of diseases. Investigations involving MET recombinant proteins not only facilitate the identification of potential therapeutic interventions but also hold promise for biomarker development, improving patient stratification and personalized medicine approaches in cancer treatment.
